SEC Comment Letter for PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Aug 29, 2022
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Aug. 29, 2022 · CIK: 0001472091 · Accession: 0000000000-22-009367
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267041
Letter
United States securities and exchange commission logo August 29, 2022 Frank Bedu-Addo, Ph.D. Chief Executive Officer PDS Biotechnology Corporation 25B Vreeland Road, Suite 300 Florham Park, NJ 07932 Re:PDS Biotechnology Corporation Registration Statement on Form S-3 Filed August 24, 2022 File No. 333-267041 Dear Dr. Bedu-Addo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Emilio Ragosa, Esq.
Show Raw Text
United States securities and exchange commission logo
August 29, 2022
Frank Bedu-Addo, Ph.D.
Chief Executive Officer
PDS Biotechnology Corporation
25B Vreeland Road, Suite 300
Florham Park, NJ 07932
Re:PDS Biotechnology Corporation
Registration Statement on Form S-3
Filed August 24, 2022
File No. 333-267041
Dear Dr. Bedu-Addo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Emilio Ragosa, Esq.